AIM ImmunoTech (AIM) announced its initiation of a plan to advance Ampligen as a vaccine adjuvant for avian influenza as part of the Company’s ...

Klaus joins Epitopea after serving as Chief Development Officer (CDO) at Nykode Therapeutics, where he oversaw clinical development, regulatory affairs, and project management across oncology, ...

With the growing understanding that ATTR-CM may be a significant underlying cause of HFpEF, how might AstraZeneca’s research influence the development of therapies for this subset of heart ...

AstraZeneca’s planned vaccine hub for Liverpool is off the table - business editor Karl Matchett and Whitehall editor Kate ...

Pharma giant AstraZeneca urged Britain to improve the environment for businesses in order to drive investment, days after it ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We get into more ...

LONDON, Feb 3 (Reuters) - Britain on Monday hit back at AstraZeneca over the collapse of a 450 million pound ($558.5 million) investment, saying the drugmaker had scaled back the research and ...

Britain on Monday hit back at AstraZeneca over the collapse of a 450 million pound ($558.5 million) investment, saying the ...

AstraZeneca PLC (NASDAQ:AZN – Free Report) – Research analysts at Zacks Research ... focuses on the discovery, development, manufacture, and commercialization of prescription medicines.

AstraZeneca PLC (LON:AZN), a leading global biopharmaceutical company with a market capitalization of $216.74 billion, has been making significant strides in the pharmaceutical industry, particularly ...

AstraZeneca research and development oncology haematology executive vice-president Susan Galbraith stated: “With 57% of patients still alive at three years in the ADRIATIC trial, Imfinzi has the ...

AstraZeneca is no longer pursuing plans for a 450 million pound ($558.32 million) vaccine manufacturing plant in Speke, ...